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Specific criteria have been established to define the occurrence of myocardial infarction (MI) and stroke in cardio-
vascular clinical trials, but there is not a consistent definition for heart failure. Heart failure events appear to occur at a
rate that is similar to stroke and MI in trials of hypertension, hyperlipidaemia, diabetes, and coronary heart disease, yet
a consistent approach to defining heart failure events has not yet been realized. The wide range of definitions used in
clinical trials makes it difficult to interpret new data in the context of existing literature. This inconsistency has led to
challenges in determining the incidence of heart failure in cardiovascular studies and the effects of interventions on
these endpoints. This paper examines issues related to defining heart failure events in cardiovascular clinical trials and
presents a definition to formally address this issue.
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Background and scope
of the problem
Criteria have been established to define the occurrence of myo-
cardial infarction (MI) or stroke in cardiovascular clinical trials,
but a consensus definition has not been reached for heart failure
events.1– 3 In December 2005, a group of cardiovascular clinical tri-
alists, biostatisticians, National Institutes of Health (NIH) scientists,
regulators, and pharmaceutical industry scientists met to discuss
current issues related to cardiovascular clinical trials. This manu-
script summarizes the group’s discussion on the methodology of
defining heart failure events in cardiovascular trials.
Overview of heart failure
definitions
The definition of heart failure events varies widely across the spec-
trum of cardiovascular clinical trials (see Supplementary material
online, Table S1). Specific definitions are not provided in many pub-
lications (even though they may be defined in the trial protocol),
and this practice prevents the reader from gaining a full under-
standing of the heart failure event. Majority of cardiovascular
trials has used endpoint committees to adjudicate events using pre-
specified definitions (see Supplementary material online, Table S1).
Significance of heart failure events
relative to stroke and myocardial
infarction
A review of published clinical trials in various cardiovascular con-
ditions shows that the incidence of heart failure is highly variable,
possibly because of varying definitions as well as differing risk of
the population under study. In general, the incidence of heart
failure is similar to that of other important endpoints that do
have established event criteria, such as stroke and MI (see
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Supplementary material online, Table S2). This observation is con-
sistent across the spectrum of cardiovascular studies.4– 8
The accurate recognition of heart failure events is important
because of the poor outcomes associated with heart failure.9 –13
Heart failure as a clinical event is important to detect, not only
because of its associated morbidity and mortality, but also
because of its societal burden.14
Heart failure events may reflect myocardial injury and/or patho-
physiologic progression. The altered haemodynamics, elevated
neurohormones, and increased filling pressures that occur in the
setting of worsening heart failure may lead to myocardial injury
or necrosis.15 Several studies have reported troponin release in
patients hospitalized for worsening heart failure, which may
reflect myocardial damage leading to worsening, or alternatively,
myocardial damage due to the exacerbation of heart failure.16 –26
Although most patients improve symptomatically and survive to
hospital discharge, the episode suggests that such patients may
be functioning near the limits of their cardiovascular reserve and
that they are prone to further episodes and an adverse
outcome. Prior heart failure hospitalization predicts all cause mor-
tality.27 Thus, correctly identifying heart failure events may aid in
subsequent risk stratification.
Occurrence of heart failure events
in non-heart failure clinical trials
Heart failure events have been reported in many hypertension
trials, and the rate is similar to or higher than that for stroke
and MI in most of these studies (see Supplementary material
online, Table S2). In comparison to the hypertension literature,
fewer lipid lowering trials have reported the incidence of heart
failure events (see Supplementary material online, Table S2).
However, when reported, heart failure event rates were similar
to, and in some studies higher than, stroke rates. In general, the
rate of coronary heart disease or MI was higher than heart failure.
Heart failure events are especially important to evaluate in dia-
betes trials because of the potential for diabetes treatments to
cause or exacerbate heart failure, and because diabetes is a risk
factor for heart failure development.28,29 For example, in the Pro-
spective Pioglitazone Clinical Trial in Macrovascular Events
(PROactive) trial, the rate of heart failure appeared to be higher
than either stroke or non-fatal MI over 34.5 months of follow-up.30
The incidence of heart failure hospitalization in coronary heart
disease clinical trials is also similar to the incidence of stroke and
MI (see Supplementary material online, Table S2).
Occurrence of heart failure events
in heart failure clinical trials
Not surprisingly, worsening of or hospitalization for heart failure is
a frequent event in clinical trials of patients with heart failure,
whereas MI and stroke account for a smaller proportion of
events (see Supplementary material online, Table S2). This obser-
vation may be due to the fact that patients do not survive long
enough after a heart failure diagnosis to experience MI or stroke
events, yet hospitalizations for heart failure are quite common.
Another potential explanation may be that patients with heart
failure are possibly more likely to die suddenly from MI and
stroke than to experience these events as non-fatal outcomes.31
The observation that heart failure events occur with a much
higher frequency than stroke or MI events is consistent across
chronic heart failure studies (see Supplementary material online,
Table S2). However, the definition used to classify heart failure
events differs across trials (see Supplementary material online,
Table S1), as does the process to confirm the event classification.
In heart failure trials, hospitalization is generally used to identify
the event, although in some cases administered treatments or
change in therapy are also used. The differences in these definitions
contribute to difficulties in data interpretation.
Occurrence of heart failure events
in observational studies
The incidence of heart failure is also similar to the incidence of
stroke or MI in observational studies. The age adjusted biennial
rate of heart failure per 1000 was 13.9, and the age adjusted
rate of stroke was 12.4 among hypertensive men in the Framing-
ham Heart Study.32 The Cardiovascular Health Study reported a
heart failure incidence of 19.3 per 1000 person years; the rate of
first hospitalized MI or coronary heart disease death was 19.2
events per 1000 person years.33
The influence of therapy on heart
failure events in cardiovascular
non-heart failure clinical trials
Importantly, heart failure events are modifiable with drug therapy
even in populations in which heart failure has not been previously
identified. In addition, the extent to which heart failure risk can be
lowered is comparable to risk reductions of other important end-
points such as MI or stroke (see Supplementary material online,
Table S2). Thus, accurately defining heart failure events is also
relevant from the standpoint of initiating effective treatment
options.
Hypertension
ACE-inhibitors and angiotensin receptor blockers (ARBs) were
associated with a significant reduction in heart failure events as
compared to placebo in a meta-analysis of 29 hypertension trials
representing 162 341 subjects (Figure 1A and B).34 A non-significant
trend towards the increased heart failure events was observed
with the calcium channel antagonist vs. placebo comparison
(Figure 1A).34 Similar findings were observed in the ALLHAT
study, where amlodipine was associated with a greater heart
failure risk as compared to chlorthalidone.35 Lisinopril was associ-
ated with a greater heart failure risk as compared to chlorthalidone
during 1 year, but there were no differences between chlorthali-
done and lisinopril during subsequent years, whereas the risk
associated with amlodipine persisted.
The mechanism of action supporting these observed effects on
heart failure events is not known. The Blood Pressure Lowering
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Treatment Trialists’ Collaboration meta-analysis found a predict-
able and direct association between blood pressure reduction
and stroke, coronary heart disease, major cardiovascular events,
cardiovascular death, and total mortality. However, heart failure
events were not related to the changes in blood pressure.34 This
observation raises the hypothesis that blood pressure may be an
appropriate surrogate marker of MI and stroke events, but it
may not adequately predict heart failure events. Another possible
explanation for the lack of an observed relationship between blood
pressure lowering and heart failure events may be that the incon-
sistent definitions used for heart failure among hypertension trials
decreased the ability to detect such an association.
Figure 1 (A) Effect of drug Therapy on Cardiovascular Outcomes in the Blood Pressure Lowering Treatment Trialists’ Collaboration
Meta-Analysis. Reprinted with permission from ref. 34. (B) Effect of ARBs on Cardiovascular Outcomes in the Blood Pressure Lowering Treat-
ment Trialists’ Collaboration Meta-Analysis. Reprinted with permission from ref. 34.
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Hyperlipidaemia
Reductions in heart failure events have also been observed in statin
trials (see Supplementary material online, Table S2). The findings of
these analyses have led to interest in exploring statins as potential
therapy for heart failure.36,37 For example, a reduction in heart
failure hospitalizations was reported in the Treating to New
Targets (TNT) study (HR 0.74, 95% CI 0.59–0.94; P ¼ 0.01). Sig-
nificant reductions in cerebrovascular events (HR 0.77) and
major coronary heart events (HR 0.80) were also observed.38
Heart failure as an adverse event
Accurately defining heart failure is important not only for detecting
signals of treatment efficacy, but also for identifying potential safety
issues. Some cardiovascular studies have detected an association
between pharmacologic therapy and heart failure risk. Both doxazo-
sin and amlodipine were associated with higher rates of heart failure
in ALLHAT when compared to diuretics and ACE inhibitors.39,40
The observation of increased heart failure events in the doxazosin
arm prompted early discontinuation of that study arm.40 In the Val-
sartan Antihypertensive Long-term Use Evaluation (VALUE) trial,
the relative risk for HF events was higher with amlodipine as com-
pared to valsartan.41 These findings have stimulated some debate
on whether the events detected in these trials were heart failure,
or if they were confounded by diuretic withdrawal in ALLHAT or
peripheral edema side effects associated with amlodipine. These
examples illustrate the challenges clinical researchers face because
of the lack of a standard heart failure definition.
Similar concerns were evident with pioglitazone in The Prospec-
tive Pioglitazone Clinical Trial in Macrovascular Events (PROactive)
trial.30 In the PROactive study, a lower combined rate of death, MI,
acute coronary syndrome, stroke, cardiac intervention, leg amputa-
tion, or leg revascularization was observed for pioglitazone treated
patients as compared to placebo.30 However, the rate of any
reported heart failure was higher (see Supplementary material
online, Table S2).30 In this study, heart failure events were deter-
mined by the investigator, and non-fatal events were not adjudi-
cated. Edema in the absence of heart failure was also higher in
pioglitazone treated patients (21.6 vs. 13%). Loop diuretics were
added in 7.7% of pioglitazone patients and 5.4% of placebo
patients. It is possible that some of the non-adjudicated heart
failure events could have been edema without heart failure. To
address this concern, Ryden et al. conducted a post hoc, blinded,
independent adjudication of investigator reported serious heart
failure events, which confirmed the investigator reported find-
ings.42 As illustrated by each of these studies, the true presence
of heart failure is difficult to assess without concrete definitions
or evidence of structural myocardial changes consistent with
heart failure.
Criteria for a heart failure event
Event definitions in non-heart failure
studies
A major problem of defining new-onset heart failure in trials is the
lack of a robust method to identify when breathlessness or ankle
swelling is due to heart failure or another cause. The need for hos-
pitalization or administration of intravenous medications may be
adequate to capture more severe heart failure events and is
useful as evidence of exacerbation of the underlying disease in
trials of heart failure, but in low risk, primary prevention popu-
lations, objective criteria of myocardial dysfunction is probably
necessary to confirm a new heart failure diagnosis, as is clear in
diagnostic guidelines.43 For example, objective measures of
cardiac dysfunction in the PROactive trial may have helped to
determine whether ankle edema was due to the localized collec-
tion of fluid or really reflected heart failure.30 However, assess-
ments such as echocardiography are costly and would not be
feasible in most large clinical trials. BNP may also be a useful diag-
nostic tool to establish or refute the occurrence of a heart failure
event. BNP would serve as a less expensive measure than echocar-
diography or other assessments of myocardial structure. In con-
junction with symptoms, BNP is associated with high sensitivity
and specificity for heart failure.44 Either BNP or NT-proBNP
could be used; however, BNP may be a less complicated
measure than NT-proBNP, since the cutoffs for NT-proBNP
vary with age (see Supplementary material online, Table S3).45,46
If de novo HF is to be ascertained, the criteria used, whether echo-
cardiography, BNP, or other objective assessments, should be con-
trasted against normal baseline measures.
The sensitivity (proportion of true positives) and specificity
(proportion of true negatives) to detect heart failure events
differs according to how the event is defined. Investigator ascer-
tainment is likely associated with a moderately high sensitivity,
but relatively low specificity. Investigators may be likely to detect
heart failure when it exists, but they are less able to differentiate
correctly between true heart failure and a clinical situation that
is suspicious but actually negative for heart failure. The definition
that combines signs and symptoms with direct (echocardiography)
or indirect (BNP) evidence of cardiac dysfunction is likely to
produce the greatest sensitivity and specificity.
In some cases, an adjudication committee, blinded to trial treat-
ment assignment, may be necessary to establish the heart failure
diagnosis. Adjudication committees apply systematic criteria to
events, which may be important particularly for events such as
heart failure where uniform criteria are lacking. In the Cardiovascu-
lar Health Study, the investigators initially classified all events, and a
rigorous adjudication process followed.47– 49 The agreement
between the initial and adjudicated assessment was the greatest
for MI and stroke endpoints (86.1 and 91.8%, respectively).47
The concurrence between the initial and adjudicated assessment
for heart failure was lower at 70.4%, illustrating the challenges
investigators face with classifying heart failure events when a
specific, uniform definition is lacking. In ALLHAT, there was 83%
agreement on a subset of heart failure hospitalization events
between the adjudication committee and site investigators.40
However, in the INSIGHT trial, 114 events were considered
heart failure by the investigator while the CEC identified only 50
events that met heart failure criteria, a 56% reduction from the
investigator assessment.50 In the recent analysis of the PROactive
study, investigator reported and adjudicated events were quite
similar, with investigators reporting a heart failure hospitalization
rate of 5.7 and 4.1% in the pioglitazone and placebo groups,
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respectively. The adjudicated heart failure hospitalization rate was
5.5 and 4.2%.42
A consistent definition would ensure that heart failure events in
non-heart failure trials are accurately reported and that outcomes
can be interpreted across heart failure trials. Both the presence of
heart failure and treatment for heart failure should be documen-
ted. Several criteria should be required for an event to be classified
as heart failure. For a non-heart failure trial, it may also be import-
ant to distinguish among patients with a pre-existing heart failure
substrate vs. those without. The PROactive example is useful to
further illustrate this concept.30 These study results cause one to
question whether the volume overload associated with pioglita-
zone was sufficient to cause heart failure in a patient with a
normal heart, or if the development of heart failure was limited
to those patients who had an abnormal cardiac substrate such
that the volume overload produced by pioglitazone caused symp-
toms of heart failure. This distinction may be useful to accurately
define and characterize the event. The definition should also be
clinically meaningful. Death due to heart failure is an important
event, but heart failure hospitalization or functional incapacity is
equally important in reporting trial results. Beyond these basic
requirements, several methods to define heart failure events
have been used.
Heart failure hospitalization
Hospital admission is the main factor used by many clinical trials to
define heart failure events. Hospitalization is a more objective
outcome as compared to signs and symptoms. In addition, it is
clinically significant since it is associated with poor prognosis.
However, several difficulties are associated with using hospitaliz-
ation alone as a criterion. First, the hospitalization threshold
differs across institutions and regions of the world, and this may
account for some of the variability in reported events. Second,
some patients with a previous diagnosis of heart failure who
develop worsening heart failure symptoms will be managed as out-
patients in disease management programs. Other patients who lack
access to such intensive monitoring and care programs may be
hospitalized for identical symptoms. These practice pattern vari-
ations may confound the results of clinical trials that rely on hos-
pital admissions to define heart failure events, particularly in
international trials, where differences in patterns of care may be
particularly evident.
Treatment requirements to establish
heart failure
The administration of intravenous therapy for heart failure is also
used to identify heart failure events. However, this requirement
is problematic for similar reasons. Practice patterns for prescribing
intravenous diuretics, vasodilators, or inotropes differ across insti-
tutions and countries. European physicians tend to use intravenous
diuretics less often than physicians in the USA. Conversely, inves-
tigators in the USA are less likely to use intravenous inotropes than
their European colleagues, although this observation may be
related to the clinical characteristics and severity of the heart
failure presentation.9,12,51 –53 Thus, using intravenous therapies as
a mechanism to define heart failure events is challenging because
whether or not a patient meets the definition may be dependent
on factors not directly related to the patient’s clinical condition,
such as local practice patterns.
Reporting of fatal and non-fatal heart
failure events
Both fatal and non-fatal heart failure events are important to ascer-
tain in clinical trials, but these distinctions are inconsistently
reported in published papers.54 It is important to ascertain the
number of patients with heart failure, MI, or stroke events and sub-
sequently classify these events according to whether the patient
did or did not survive over a given time period. Heart failure
death is often not distinguished from all cause or cardiovascular
mortality. Thus, it is difficult to determine the breakdown of fatal
and non-fatal heart failure events in clinical trial reports. Of the
non-heart failure cardiovascular trials reporting such data, the pro-
portion of patients experiencing a fatal event attributed to heart
failure is quite low in comparison to the non-fatal heart failure
events.55 –57
Fatal heart failure events occur at a higher rate in heart failure
trials than in non-heart failure cardiovascular trials, but the non-
fatal event rate is still generally several fold higher than the fatal
event rates.58,59 Fatal heart failure events occur at a higher rate
in more severe heart failure populations, such as that studied in
the Randomized Aldactone Evaluation Study (RALES).60
Within the context of fatal heart failure events, mode of death
may be important to characterize for some types of trials, particu-
larly for trials of implantable cardioverter defibrillators (ICDs).
Although these devices reduce sudden death, pump failure death
may either be neutrally affected or increased. Data from the Multi-
center Automatic Defibrillator Implantation Trial (MADIT) suggest
that ICD therapy is associated with a shift in risk from sudden
death to a subsequent heart failure risk.61
Challenges associated with
defining events
Heart failure as a complication
of other conditions
Heart failure may occur as a result of other disease processes, such
as MI, atrial fibrillation, or pulmonary disease, or heart failure may
be exacerbated by these diseases. It is difficult to determine the
classification priority when these events occur simultaneously.
Adjudication committees are often very helpful in these
circumstances.
Defining the syndrome: systolic vs.
diastolic heart failure
Defining heart failure events is uniquely challenging in patients with
diastolic heart failure or heart failure with preserved systolic func-
tion (HF-PSF). In patients with impaired left ventricular function,
majority of hospitalizations is attributable to heart failure.
However, non-cardiovascular causes of hospitalization and death
are common in patients with HF-PSF. These patients have many
comorbidities including atrial fibrillation, anemia, renal dysfunction,
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pulmonary disease, cerebrovascular disease, and depression.62
Thus, a more stringent heart failure event definition may be
needed in these patients to ensure accurate and relevant event
classification. Echocardiography may also be useful in this setting
to document diastolic dysfunction.63
Developing a meaningful event definition
Heart failure events in clinical trials should be defined in a clinically
meaningful way such that they are relevant to clinicians, regulators,
and patients. Hospitalization is generally always clinically relevant
for both physicians and patients. Using symptoms to define heart
failure may be more challenging, because symptoms such as
dyspnea, although clinically relevant, can be non-specific for
heart failure. Using non-specific criteria to classify heart failure
events may be more problematic in non-heart failure cardiovascu-
lar clinical trials than in heart failure trials, where worsening
dyspnea is more likely to represent heart failure. In heart failure
trials, the need for intravenous vasoactive or diuretic therapy is
often a component of the heart failure event definition. Creating
a definition of this nature may identify a more severe heart
failure event, but other less severe heart failure events may
remain undetected. Emergency department admissions have been
used to define heart failure events in some trials, and it may be
an important component of the definition, particularly if assess-
ments of resource utilization are of interest.
It is impractical to create a heart failure definition that is clinically
relevant and satisfies all types of trials across multiple disciplines.
However, it may be feasible to propose a standard, uniform set
of criteria that would provide the framework to define heart
failure across trials. This definition could be used across all non-
heart failure cardiovascular clinical trials and heart failure trials
where appropriate. Additional uniform definition components
could be added to this standard heart failure event definition in
heart failure trials as needed to address specific issues related to
the intervention or the severity of disease in the population
under study. We propose that a consensus definition should
address the following concepts: (i) objective evidence of cardiac
dysfunction (e.g. cardiac imaging, BNP) and that the patient has
and is receiving treatment for heart failure; (ii) the event is clinically
meaningful; (iii) the event captures the course of the disease; (iv)
the event is acceptable to regulatory bodies. Hospitalization
should be included in the definition.
The meeting participants developed a set of definitions for heart
failure. These include new onset heart failure as a diagnosis in
patients without known heart failure enrolled in non-heart failure
trials, heart failure as a new event in patients with no previously
known heart failure, and heart failure as an event in patients with
known heart failure enrolled in non-heart failure trials (see Sup-
plementary material online, Table S3). Investigators may adapt
this proposed definition to meet the needs of a particular clinical
trial. In some trials, a more stringent definition may be desired
and all of the proposed components may be applied. For other
trials, a less stringent definition may be appropriate and only
specific aspects of the definitions may be used. These definitions
are intended to be a framework that may be adapted to the cir-
cumstances of the clinical trial and study population. Of course,
the definition should be included in the trial protocol, and the
definition used should be reported explicitly in the trial report
to facilitate interpretation of the heart failure results. These defi-
nitions also provide an opportunity for research. Data collected
in clinical trials may be tested against these definitions to validate
them and to determine the prognosis of patients identified as
having new onset heart failure. These definitions may be continu-
ally refined as needed, as experience using them accumulates.
Several areas where further discussion is needed before a con-
sensus can be reached include: (i) development of a method to
avoid or minimize confounding by variations in practice when
heart failure events are defined by hospitalizations and/or treat-
ment interventions; (ii) assessment of events in the context of
comorbidities; (iii) determination of whether adjudication commit-
tees are necessary to evaluate heart failure events in all major trials
or whether more robust case report forms and protocols are ade-
quate to evaluate events. We put forth definitions for further con-
sideration by the cardiovascular clinical trial community.
Conclusion
Heart failure is a frequent event in cardiovascular non-heart failure
trials. It is also a serious event associated with poor outcome. It is a
complex clinical event represented by a variety of signs and symp-
toms. The symptom assessment is often subjective; thus, similar
symptoms may be described differently in individual patients. In
addition, the pathophysiology is heterogeneous, making precipitat-
ing factors difficult to ascertain in some patients. Despite these
challenges, a consistent approach to defining heart failure events
in cardiovascular clinical trials is needed. In the absence of a con-
sensus definition, clinical trial data may not reliably describe the
occurrence of heart failure events, the effect of treatment on
heart failure events, or the differentiation between heart failure
and non-heart failure events.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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